Hengdian Industrial Corporation invested in the establishment of Dongyang Synthetic Chemical Plant to produce pharmaceutical intermediates. By 1990, this had expanded with the addition of two additional chemical plants in Dongyang. These three plants now serve as Apleoa’s Tospo, Jiayuan, and Kangyu Pharmaceutical facilities.
Reverse merger was completed that replaced a part of the pharmaceutical business and resulted in a listing to Qingdao Dongfang. This led to a transformation of the company’s corporate system.
Completed a major asset restructuring and issued shares to purchase assets and raise funds to support pharmaceutical assets for the overall Hengdian Group’s pharmaceutical business listing.
Completed an optimization of organizational management structure. The development strategy of “refining raw materials, strengthening CDMO, and optimizing finished dosage forms” was implemented along unified strategy, culture, and management approaches.
Invested in capital expansions with a focus on operational talent acquisition and optimized R&D capabilities in alignment with new corporate vision and mission statements.
Launch of first North American early R&D center in Boston, MA in the United States. U.S. facility will perform early discovery and development services and seamlessly scale projects into Apeloa’s global network of facilities for advancement and manufacturing.